Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke

Archives of Neurology

Volumn 67, Issue 5, 2010, Pages 559-563

  Prabhakaran, Shyam ^a   Rivolta, Juan ^b   Vieira, Julio R ^b   Rincon, Fred ^b   Stillman, Joshua ^b   Marshall, Randolph S ^b   Chong, Ji Y ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ACUTE DISEASE; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; IATROGENIC DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

EID: 77952271191     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.25     Document Type: Article

References (24)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
2. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissuetype plasminogen activator for treatment of acute stroke: the Standard Treatment With Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145-1150.
3. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34(12):2847- 2850.
4. Steiner T, Bluhmki E, Kaste M, et al; ECASS Study Group. The ECASS 3-hour cohort: secondary analysis of ECASS data by time stratification. Cerebrovasc Dis. 1998;8(4):198-203. (Pubitemid 28342442)
5. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rt-PA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. 2001;32(1):12-16. (Pubitemid 32063817)
6. Schlegel DJ, Tanne D, Demchuk AM, Levine SR, Kasner SE; Multicenter rt-PA Stroke Survey Group. Prediction of hospital disposition after thrombolysis for acute ischemic stroke using the National Institutes of Health Stroke Scale. Arch Neurol. 2004;61(7):1061-1064. (Pubitemid 38915947)
7. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679-1685.
8. NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28(11):2109-2118.
9. Bravo Y, Marti-Fabregas J, Cocho D, et al. Influence of antiplatelet pretreatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis. Cerebrovasc Dis. 2008;26(2):126-133.
10. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, De Keyser J, Luijckx GJ. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65(5):607-611. (Pubitemid 351679654)
11. Adams HP Jr, del Zoppo G, Alberts MJ, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655-1711.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of ORG 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
13. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
14. van Walraven C, Austin PC, Oake N, Wells P, Mamdani M, Forster AJ. The effect of hospitalization on oral anticoagulation control: a population-based study. Thromb Res. 2007;119(6):705-714.
15. Ay H, Arsava EM, Gungor L, et al. Admission international normalized ratio and acute infarct volume in ischemic stroke. Ann Neurol. 2008;64(5):499-506.
16. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm. 2008;5(10):1365-1372.
17. NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke. 1997;28(11):2119-2125.
18. Larrue V, von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438-441.
19. Schmülling S, Rudolf J, Strotmann-Tack T, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy, and the risk of early intracerebral hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2003;16(3):183-190.
20. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.
21. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017-1025.
22. Hacke W, Kaste M, Fieschi C, et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245-1251.
23. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S; ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial. JAMA. 1999;282(21):2019-2026.
24. Illoh OC, Illoh K. Thrombolytic-associated coagulopathy and management dilemmas: a review of two cases. Blood Coagul Fibrinolysis. 2008;19(6):605-607.